Hypertension, poor glycemic control, and microalbuminuria in Cuban Americans with type 2 diabetes

International Journal of Nephrology and Renovascular Disease

Volumn 4, Issue , 2011, Pages 35-40

  Zarini, Gustavo G ^a   Exebio, Joel C ^a   Gundupalli, Deva ^a   Nath, Subrata ^b   Huffman, Fatma G ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b University of Texas Health Science Center   (United States)

Author keywords

A1c; Blood pressure; Cardiovascular disease; Hispanics; Kidney function

Indexed keywords

ALBUMIN; HEMOGLOBIN A1C;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EARLY DIAGNOSIS; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HISPANIC; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TEST STRIP; URINALYSIS;

EID: 79952980012     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/IJNRD.S15873     Document Type: Article

References (29)

1. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310(6): 356-360.
2. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997;157(13):1413-1418.
3. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160(8):1093-1100.
4. Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int. 1999;55(1):1-28.
5. Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158(9):998-1004.
6. Park JY, Kim HK, Chung YE, et al. Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes. Diabetes Care. 1998;21(4):530-534.
7. Aponte J. Diabetes-related risk factors across Hispanic subgroups in the Hispanic health and nutritional examination survey (1982-1984). Public Health Nurs. 2009;1:23-38.
8. Rodriguez RA, Hernandez GT, O'Hare AM, et al. Creatinine levels among Mexican Americans, Puerto Ricans, and Cuban Americans in the Hispanic Health and Nutrition Examination Survey. Kidney Int. 2004;66(6):2368-2373.
9. Smith CA, Barnett E. Diabetes-related mortality among Mexican Americans, Puerto Ricans, and Cuban Americans in the United States. Rev Panam Salud Publica. 2005;18(6):381-387.
10. Centers for Disease Control and Prevention: 2007 National Diabetes Fact Sheet. http://www.cdc.gov/diabetes/pubs/estimates07.htm#4. Accessed October 5, 2010.
11. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc. 2003;289(19):2560-2572.
12. Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985;122:51-65.
13. Nath SD, Huffman FG. Validation of a semiquantitative food frequency questionnaire to assess energy and macronutrient intakes of Cuban Americans. Int J Food Sci Nutr. 2005;56:309-314.
14. American Diabetes Association. Standards of medical care in diabetes: 2010. Diabetes Care. 2010;33 Suppl 1:S11-S61.
15. Davidson MB, Bazargan M, Bakris G, et al. ImmunoDip: an improved screening method for microalbuminuria. Am J Nephrol. 2004;24(3): 284-288.
16. Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002;48(3):436-472.
17. Rossi MC, Nicolucci A, Pellegrini F, et al. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAUND (Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes) Study. Nephrol Dial Transplant. 2008;23(4):1278-1284.
18. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J. 2000; 321(7258):405-412.
19. Thomaseth K, Pacini G, Morelli P, et al. Importance of glycemic control on the course of glomerular filtration rate in type 2 diabetes with hypertension and microalbuminuria under tight blood pressure control Nutr Metab Cardiovasc Dis. 2008;18(9):632-638.
20. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Br Med J. 1998; 317(7160):703-713.
21. Persson F, Rossing P, Hovind P, et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMAU 2) study. Scand J Clin Lab Invest. 2008;68(8):731-738.
22. Stehouwer CD, Gall MAU, Twisk JW, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51(4):1157-1165.
23. Araki S, Haneda M, Sugimoto T, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes. 2005;54(10):2983-2987.
24. Chan JC, Ko GT, Leung DH, et al. Long-term effects of angiotensinconverting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int. 2000;57(2):590-600.
25. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. N Engl J Med. 2001;345(12):870-878.
26. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106(6):672-678.
27. Gaede P, Tarnow L, Vedel P, et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant. 2004;19(11):2784-2788.
28. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J. 2000;321:1440-1444.
29. American Diabetes Association. Standards of medical care in diabetes: 2009. Diabetes Care. 2009;32 Suppl 1:S13-S61.